Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do not worry I will get money to buy the cheaps
I bought in another 250K shares, good point to get in
Definitely not, patience is the key. I will find the funds to buy more!!!
yes, based on it readily marketable isopet, and soon to be approved trial of radiogel for human, after two great conferences of widest exposure, vivos is setting its new stage of aiming high. it can come in just in a thunder of roaring.
Gel technology offers a promising approach toward cancer treatment
Fist in aminals then in Humans
https://energyenvironment.pnnl.gov/highlights/highlight.asp?id=518
Do your DD, this is about PNNL
COMPANY OVERVIEW by redchip.com
https://www.redchip.com/company/Biotech/RDGL/376/RDGL
Vivos Inc (OTC: RDGL) is engaged in the development of a brachytherapy device for the treatment of cancerous tumors. Brachytherapy uses radiation to destroy tumors by placing a radioactive isotope inside the treatment area. Currently, the company is pursuing FDA approval of its brachytherapy device, RadioGel, initially for the treatment of advanced basal and squamous skin cancers. Concurrently, the Company is pursuing development of veterinary applications for a range of cancers in collaboration with four leading university veterinary hospitals. Veterinary applications should have a faster path to revenue for RDGL, while providing data supporting the safety and therapeutic effectiveness of RadioGel. RDGL’s RadioGel requires no pre-market approval for pet therapy and the Company plans to generate near term revenue from veterinarian clinics and international licensing by 1Q18.
VALUE PROPOSITION
RDGL is in late-stage development of a brachytherapy device for medical and veterinary cancer treatment applications. The Company plans to generate near-term revenue from veterinarian clinics and international licensing while pursuing FDA approval for multiple cancer indications. RDGL’s cancer treatment can disrupt the cancer treatment market, offering the potential upside of a drug with lower cost and shorter approval path of a device. Additionally, companies involved in brachytherapy treatment, such as Elekta AB ($3.5 billion) and Varian Medical Systems ($9.2 billion), provide an idea of valuation potential for RDGL, which represents significant upside from current levels.
INVESTMENT HIGHLIGHTS
Plans to generate near-term revenue from veterinarian clinics and international licensing by 1Q18; RDGL is in late-stage development of a brachytherapy device for medical and veterinary cancer treatment applications
Company has the potential to disrupt the cancer treatment market with lower cost and shorter approval path of a cancer treatment device
Brachytherapy market is expected to reach $245 million by 2018
RDGL’s next-generation radiopharmaceutical therapeutic device uses hydrogel that is liquid at room temperature and solidifies at body temperate and locks in the particles
Company’s RadioGel requires no pre-market approval for pet therapy
Cancer is the leading cause of death for 32% of cats and 50% of dogs over age 10, Treating 10% of pet cancers at $5,000 average per treatment, generates $40 million annual revenue
Currently testing at leading university veterinary programs to demonstrate therapy across multiple indications
Strong leadership and word-class medical advisory board
More than 125 years combined experience; input from Mayo Clinic doctors
Another great result of Y-90 in Human cancer treatment
Radiogel has its unique features, it is much better delivery approach which immobilized in place with much less harm to normal tissue, it will be approved in human clinic usage!!!
Am J Surg. 2018 Mar;215(3):467-470. doi: 10.1016/j.amjsurg.2017.11.022. Epub 2018 Feb 2.
Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma?
Shaker TM1, Chung C2, Varma MK3, Doherty MG3, Wolf AM4, Chung MH4, Assifi MM5.
Author information
Abstract
BACKGROUND:
Selective internal radiation therapy (SIRT) with Ytrrium-90 (Y-90) has been used to treat hepatic malignancies with success. This study focuses on the efficacy and safety of Y-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma (ICC).
METHODS:
A single-institution retrospective case review was performed for patients with unresectable and metastatic ICC treated with Y-90 between 2006 and 2016.
RESULTS:
Seventeen patients with ICC underwent 21 Y-90 treatments. Four patients had undergone prior liver resection, and six patients had extrahepatic disease at the time of treatment. Five year overall survival was 26.8%, with a median survival of 33.6 months. One patient underwent margin negative liver resection after a single treatment. Complications were appreciated in two cases. Ninety-day mortality was 0%.
CONCLUSION:
Treatment of ICC using Y-90 is a safe and promising procedure. Further research is needed to clarify its role in the treatment of unresectable and metastatic ICC.
Radiogel will be huge in human cancer treatment!!!
A great indirect evidence of its huge application in combination treatment for HCC
https://www.ncbi.nlm.nih.gov/pubmed/29845347
Cardiovasc Intervent Radiol. 2018 Nov;41(11):1799-1802. doi: 10.1007/s00270-018-1993-1. Epub 2018 May 29.
Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.
Wehrenberg-Klee E1, Goyal L2, Dugan M3, Zhu AX2, Ganguli S4.
Author information
Abstract
Nivolumab has recently received approval by the Food and Drug Administration for treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Nivolumabs' overall response rate of 20% (El-Khoueiry et al. in Lancet 389:2492-2502, 2017) is a step forward for these patients, but there is significant room for improvement. We describe a case of combining Y-90 radioembolization with nivolumab for treatment of angioinvasive HCC, which successfully bridged patient to partial hepatectomy. Surgical pathology showed negative margins with complete pathological response. With the introduction of immunotherapy for HCC, combining Y-90 radioembolization with immunotherapy may enhance the anti-tumoral immune response of checkpoint inhibitors.
Radiogel (RDGL), the key player will be in radiotherapy and combination cancer therapy
BEST STOCK IDEA
*US-based late-stage medical device healthcare company preparing for final FDA submission of its groundbreaking product. Human trial approval will be imminent!
* Brachytherapy (internal radiotherapy) devices for cancer treatment an industry projected to grow 250% from 2013 - 2030 with very few players.
Patented brachytherapy cancer product - Yttrium-90 RadioGel™ which is anticipated to be used as the front-line therapy for any cancerous tumor that cannot be removed by surgery;
*RadioGel is a revolutionary product developed by a team of world-class scientists with decorated backgrounds, which is a radioactive polymer is injected into any tumor then hardens to prevent any radioactivity from spreading around the body.
*The radioactive isotope RDGL uses, Y-90 produces a strong therapeutic dose that focuses its killing power to the tumor which could make traditional radiation methods obsolete, and have RDGL capture a significant portion of the projected $2.4B market.
Tiny $10 million market value of company: stock is trading at less than 2 penny per share! it can be over 100 M or 1000M soon, but do your own DD
Interstitial Therapy of Feline Sarcoma using an Injectable Y-90-Polymer Composite (Radiogel)
Darrell Fisher1, Janean Fidel2 and Megan Duffy2
http://jnm.snmjournals.org/content/59/supplement_1/1257
Objectives: Yttrium-90-polymer-composite (radiogel) may be administered directly into cancerous tissues to deliver highly localized beta radiation for therapy. In a dose-escalation study, we investigated the feasibility of treating feline sarcomas as a model for non-resectable solid tumors in man and animals to gain clinical experience and to identify optimal methods for placing the composite uniformly within target tumor tissue.
Methods: The resorbable hydrogel delivery vehicle for the Y-90-(YPO4) particles comprised a sterile, phosphate-buffered saline (PBS) solution containing a dissolved co-polymer of PLGA (poly-(DL-lactic acid-co-glycolic acid)) and PEG (poly-(ethylene glycol)) at 30 weight-percent. Prior to therapy, the hydrogel was added to a small amount of PBS containing a calibrated Y-90 activity within insoluble, high-purity yttrium-phosphate (YPO4) particles (nominally 1-3 µm dia.), and was well-mixed. The composite was injected into sarcoma tissue of four cats (one more pending) with 25-27 gage needles under ultrasound guidance using a parallel-needle grid pattern and approximate 5-mm spacings. The cats were anesthetized for the procedure with Desflurane. After injection, the solution (10-15% by tumor volume) gelled within interstitial spaces to solid phase at body temperatures approaching 37°C to contain the activity intratumorally. The cats were then placed in a radiation isolation room and monitored overnight. Planned imaging with CT was performed at 2-weeks prior to injection, immediately post-injection, and then again at 3-weeks and 6-weeks post-injection.
Results: Gelation within extracellular spaces held the Y-90-YPO4 particles in place without migration from the tumor to deliver a planned radiation absorbed dose (100 to 300 Gy) to target tissue through complete decay. Post-injection, the cats exhibited some pain in the tumors, and all had decreased appetites for 3-6 weeks post injection. At the 3-week recheck in three cats, the tumors remained stable in size. One cat was euthanized at that recheck due to health concerns unrelated to the treatment, and the tumor was harvested for examination. In one other cat, the tumor was successfully removed at the 6-week time point. In two cats, tumor removal had not yet occurred. Response of the tumor tissue to Y-90 radiation therapy post-removal was evaluated by pre-histological analysis. A definitive correlation was observed on histopathology between necrosis of tumor and sites of composite injection.
Conclusions: Our clinical team demonstrated successful placement of Y-90-polymer composite without measurable external radiation dose to any staff. The radiogel carrier materials performed as expected before and after injection. The cat patients recovered quickly from the procedure but may have experienced pain and loss of appetite related to nerve damage from needle injections. Tumors showed objective response with indications of tumor cell destruction associated with localized radiation. Support: Washington State Life Sciences Discovery Fund
Battelle Acquires over 10% of Advanced Medical Isotope Corporation
Radiogel is a true technology!!!
https://www.federallabs.org/successes/awards/awards-gallery/2013/injectable-radiogel-for-high-dose-interstitial-radiation
A team from Pacific Northwest National Laboratory (PNNL) developed and transferred a new injectable radiogel for delivering insoluble yttrium-90 — a well-established medical radioisotope with many applications in cancer treatment—microspheres to a precise location for targeted radiation therapy. This safe, effective, low-cost brachytherapy treatment allows clinicians to deliver higher doses of radiation exactly where needed while minimizing exposure to surrounding healthy tissue. Radiogels are ideal for treating solid tumors that cannot be safely removed via surgical methods.
PNNL developed the technology prior to the initiation of a technology transfer partnership. Advanced Medical Isotope Corporation (AMIC) approached PNNL seeking novel resorbable brachytherapy technology to add to its product offerings, and this technology was identified during initial discussions as having high potential to be a fit. A strong relationship was formed as the partners conducted further analyses of the technology, with PNNL acting as technical and commercialization consultant, providing AMIC with access to Laboratory resources, capabilities, and analytical results, and negotiating access terms. AMIC became the technology licensee.
The transfer effort between PNNL and AMIC began after multiple internal technology maturation funding investments had already been leveraged to hone and confirm specific technology characteristics. In September 2010, AMIC signed an exclusive license for the fast-resorbable brachytherapy seed technology. Then, in February 2011 AMIC signed a one-year option agreement for the injectable radiogel delivery mechanism, followed by proposing and being approved for a PNNL Technology Assistance Program project (provides up to one week of PNNL researcher time at no charge) to receive additional guidance on making and delivering yttrium-90 microspheres for correct tumor dosing. In March 2012, AMIC signed another exclusive license for the radiogel delivery technology.
This transfer represents a significant business growth opportunity for AMIC which, upon successfully garnering FDA approval, will have a safe and effective new treatment option to offer its customers. The licensing of this technology also helped PNNL achieve its mission to deploy lab-developed technology for societal and economic benefit, and has resulted in a strong, ongoing partnership between PNNL and AMIC that could lead to additional transfers.
Note PNNL is a world-known national lab belongs to US depart of Energy, operated by Battelle where Vivos got all the patents licenses from;
Discovery in action.These words describe what we do at PNNL, which has been operated by Battelle(Offsite link) and its predecessors since our inception in 1965. For more than 50 years, we've advanced the frontiers of science and engineering in the service of our nation and the world. We make fundamental scientific discoveries that illuminate the mysteries of our planet and the universe. We apply our scientific expertise to tackle some of the most challenging problems in energy, the environment, and national security.
Excellence in Technology Transfer
AWARD YEAR: 2013
Animal Skin Cancer Treatment Classified as a Device by FDA
https://www.americanveterinarian.com/news/animal-skin-cancer-treatment-classified-as-a-device-by-fda
Vivos Inc. announced today that it has received FDA confirmation that RadioGel, a brachytherapy tool, is classified as a device for therapy of feline sarcomas and canine soft tissue sarcomas. As per FDA recommendation, RadioGel will be marketed as IsoPet for use by veterinarians to avoid any confusion with the device used in humans.
According to a company press release, the device is comprised of highly insoluble yttrium-90 particles delivered by needle injection using a water-polymer composite for high-dose treatment of nonresectable solid tumors that cannot be treated by other means. The therapy is designed to deliver a high dose of radiation to tumor tissue, with adjacent normal tissue and organs receiving small-to-negligible radiation doses.
Vivos, which changed its name from Advanced Medical Isotope Corporation earlier this month, said it completed a feline sarcoma therapy series at Washington State University (WSU) in January. From these tests—which were designed to improve procedures and determine the optimum dose—it was determined that RadioGel was safe and effective in eliminating cancer cells.
“Obtaining this approval is an important step to set the stage for selling IsoPet to private clinics for animal therapy,” said Mike Korenko, PhD, CEO of Vivos. “By being labeled a device there are no other regulatory approvals necessary for treating skin cancer, the most common cancer in animals.”
With the FDA confirmation, the company has immediate plans to partner with leading veterinary colleges to treat animals diagnosed with cancer. In February, it plans to incorporate lessons learned from the feline study at WSU to recruit canine skin cancer patients. The dogs are scheduled to be treated at the University of Missouri. In April, the company plans to begin using IsoPet at the University of California, Davis, on dogs with prostate and liver cancers. From there, it plans to begin treatment of equine sarcoids at the University of Missouri.
Vivos said that by obtaining FDA approval in stages, it hopes to establish a faster path to commercializing the product in the veterinary sector. Ultimately, the company said it will use the data generated from its animal studies as part of the testing required by the FDA for treating skin cancer in humans.
$RDGL Keep your ??eyes on FDA Device Classification Website
they update between 11:30 PM and Midnight every Monday!!! and Human Approval through De novo Classification is WAY OVERDUE and EXPECTED any time.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?start_search=1&Center=&Panel=&ProductCode=&KNumber=&DenKNumber=&Applicant=&DeviceName=&Type=&ThirdPartyReviewed=&ClinicalTrials=&ExpeditedReview=&Decision=&DecisionDateFrom=&DecisionDateTo=10%2F04%2F2018&DeNovo=on&IVDProducts=&CombinationProducts=&ZNumber=&PAGENUM=10&sortcolumn=DecisionDateDESC …
A "Partnership" in the making w/VCA
“We believe we’re in a strong position to execute,” concluded Korenko. “As we move forward with this focused strategy multiple milestones can be achieved in the near-term setting the stage for sustainable long-term growth”
From LAR'S TWITTER
$RDGL Does anyone know how biotech works? This is medicine, for Christ's sake. You don't just get a 5000% take off from a conference, you get to present results/findings, work towards a goal in order to reach patients. This isn't a fast-food order.
From $anta's$tockClub®
@SantasStockClub
$RDGL Vivos Inc Currently has a Market Cap of $14 Million, Think about it and do the numbers. $14 Million with widespread investment coming in So wonderful to be in at this price. A couple hundred million Cap and half a dollar and that is very conservative short term.????
post from twitter
https://twitter.com/SantasStockClub
$RDGL News may be coming quick,a little elf tells me meetings are going on right NOW with Vivos and VCA Veterinary Centers of America to open regionally in their nationwide centers and this would give wide access to many pets
In the PR, READ THIS:
Dr. Mike Korenko, Vivos CEO stated “I am pleased with the strong interest in IsoPet® from the practicing veterinary oncology community and are confident that our strategic plan is on course. There are some additional exciting initiatives that we plan on pursuing in the near future. At the conference, we initiated discussions with a company that is interested in working with us on a combination therapy that would be applicable for patients with more advanced disease. We would use IsoPet® to treat the primary tumors and would follow with their immunotherapy treatment to target cells that have metastasized. This combined therapy approach would broaden the application of IsoPet® for use on these very advanced cases and would be an option for animals that were considered terminal.”
great PR at the beginning of new week
NEED TO UPDATE company presentation and conference presentation as well.
good prediction!!!at least half a dollar on the near future
we need conference PR and company presentation for INVESTORS, hopefully tomorrow PM
you scare ppl to sell but it won't be easy any more!
Be aware! Do the DD.
Vivos Inc (RDGL), previously known as Advanced Medical Isotope Corp
was covered by an independent analyst.
www.leeuwenhoeck.com
http://nebula.wsimg.com/4428bdde9198e981707684ab50fbc9d6?AccessKeyId=F1B3D293B900048B2E3E&disposition=0&alloworigin=1
More than a year ago, RDGL was valued by Van Leeuwenhoek Research for valuation of USD $35-$55 million or $0.66 - $1.00 per share, based on the potential market expectation and OS of 89M shares;
Right now RDGL has made great progress toward marketing its isopet for pet cancer treatment, getting drastic public exposure and will move next step to human trials, yes, the OS shares were diluted and will be around 1.5B, but the share price would still be worthy of a dime or more very soon.
Here are some important points from that report:
(1) According to the Center for Cancer
Research and CanineCancer.com an estimated six million dogs are diagnosed with cancer each year in the USA. According to various market reports, the market for pet cancer therapeutics is estimated to be USD 300-500 million.
(2)We feel that Y-90 RadioGel therefore has the potential to be a blockbuster (sales > 1 billion) within a few years since the therapy would be useful in a range of soft tissue cancers.
(3)Considering Y-90 Radiogel’s much higher potential commercial success compared to Sirtex’ SIR-Spheres (with total annual sales of more than AUD 200 million) and the high unmet medical need in several types of cancer, induces us to increase our valuation to USD 35-55 million;
(4) RDGL has selected skin cancer therapy for its first indication for use with the Food and Drug Administration. In the US there are 5.4 million cases of skin cancer in 3.3 million people. Treating 10% of these patients could generate annual revenue at greater than USD 1 billion. Vivos believes there are significant future opportunities in treating lymph nodes, prostate, breast, liver, pancreatic, head and neck cancers.
(5) The FDA has classified RadioGel as a device. This increase chances of a timely approval considerably. The critical path on the overall schedule to approval is firstly to complete laboratory testing concurrent with veterinary animal studies and then continue into human clinical trials. RDGL intends to align the animal treatments in its veterinarian business division to support the animal testing required for the FDA to synergize the two divisions, and potentially create time and cost savings. In this parallel strategy, the company looks to move to first-in-man trials as soon as possible, while aggressively pursuing near-term revenues through the veterinary division, IsoPet, and through licensing.
OS shares more than that, as for the value of 2.1 B, share price would be $1.5
Need PR for great conference exposure and also updated company presentation
RDGL recent solution of getting rid of toxic debt set its new stage for:
* Exposing its innovative tech and very effective cancer treatment for pets in great meetings with good standing of financial situation;
* Setting a good negotiation situation for getting any partnership or more beneficially financial funding packages from big pharma;
*quickly extending the isopet treatment for pets, accumulating many successful evidences in treating cancers;
Great DD, love it
Big pharma now are fighting for this, Partnership definitely will come true soon!
It is going to be Big, hold my shares strong until getting to the dollar land
Agree no more!!! The OS
The share with the most potential is RDGL.
https://www.iex.nl/Forum/Topic/1356083/Koffiekamer_OTC-fonds-RDGL.aspx
needed google translation into following
It is listed on the American OTC.
The price is now about 0.014 dollar.
They will soon present a product that treats certain types of cancer. Potential here is infinitely large ...
The strategic market sector of Vivos Inc. is therapeutic isotope applications. Currently, the Company is engaged in the development of RadioGel ™, a Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.
The company is engaging the FDA for permission to use RadioGel ™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel ™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness of different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can start to generate revenues through the sale of RadioGel ™ to private animal clinics.
The Company currently is outsourcing material aspects of manufacturing of its products in the United States and intends to enter into licensing arrangements outside the United States for the manufacturing and distribution of RadioGel ™ in other countries.
What is RadioGel ™?
RadioGel ™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor. This hydrogel is a liquid temperature below the body temperature, but starts to harden, when the temperature increases to normal body temperature, locking the particles in place. The particles emit a high concentration and contained irradiation to kill the tumor. The beta radiation has a short penetration distance, so there is minimal collateral damage to healthy tissues outside of the injected area.
RadioGel ™ also has a short half-life - delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other treatment options requiring up to 6 weeks or more to a complete course of radiation therapy. This is an outpatient treatment of the patient and the patient can go home with no risk to family members.
Hopefully, in faith, we are going to have this great gift by Christmas
This is a decent and real innovative tech player!!!
https://www.radiogel.com/about-1/awards-recognition/
AWARDS & RECOGNITION - VIVOS INC. (FORMERLY AMIC) HAS BEEN RECOGNIZED AS A LEADER BY LOCAL, STATE AND FEDERAL AGENCIES.
• $1.3 million U.S. Federal grant for brachytherapy
• Leaders in Healthcare Award, Seattle Business Magazine
• Federal Laboratory Consortium Award for Excellence in Technology Transfer,
*a prestigious honor recognized by the US Secretary of Energy and US Senator Murray
INDUSTRY PARTNERSand a huge one is coming
https://www.radiogel.com/about-1/industry-partners/
The Company is engaged in collaborative efforts with U.S. national laboratories and universities and with international teaming partners. The Company has active research collaborations for its brachytherapy products with Washington State University and the University of Utah as well as the Pacific Northwest National Laboratory(world wellnown national research lab), operated by Battelle.
IsoTherapudics Group
IsoTherapeutics Group is a radiopharmaceutical company that provides research and development services, including animal studies and early stage manufacturing for the purpose of aiding customers and collaborators in the development of radionuclide-based drug and device products. Current collaborators include Molecular Imaging, PerkinElmer, MD Anderson Cancer Center, University of Missouri-Columbia, Excel Diagnostics and Valco Instruments. The Company scientists, while formerly employed at The Dow Chemical Company, developed the commercial products QUADRAMET® and Iotrex®.
AMI has partnered with IsoTherapeutics Group, LLC of Angleton, TX on the manufacturing and preclinical development of Y-90 based brachytherapy. The first project between AMIC and IsoTherapeutics focuses on AMIC’s Y-90 RadioGel™ device. IsoTherapeutics is developing and executing studies, under AMI guidance, in the manner the FDA has requested, with the end goal of FDA clearance for the Y-90 RadioGel™ device.
“We are pleased to offer our services to AMI and look forward to a long and outstanding collaboration that will have a significant, positive impact on the commercialization efforts of the AMIC Y-90 brachytherapy products,” stated R. Keith Frank, Ph.D., President and CEO of IsoTherapeutics Group.
PAWSPICE
Pawspice was founded by AMI’s Veterinary Medicine Advisory Board Chair, Dr. Alice Villalobos. Pawspice is mission is to provide the highest standard of compassionate cancer treatment and end of life palliative care to advanced stage and terminal pets by providing a unique Quality of Life Care Program. As pets get older the human-animal bond gets stronger. Many books, articles and even cards describe the love and devotion that animal companions have for their owners, but overlook the dedication that pet owners have for their animal family members. Pawspice partners with pet owners and their referring veterinarians to challenge their pet's cancer and other terminal illness with a positive and compassionate approach. Supporting the heartfelt emotions of the family while providing quality of life and comfort for their deeply loved animal companions.
Pawspice has partnered with AMI to make the Company’s yttrium-90 brachytherapy treatments available to pets with tumor cancers.
Washington State University
WSU Tri-Cities, one of three urban campuses in the Washington State University system, is the only public, four-year institution in southeastern Washington. Complete your WSU degree in small-campus setting along the scenic Columbia River. Choose from 18 bachelor’s, 10 master’s degree programs and six doctoral degree programs, including business, computer science, education, engineering, liberal arts, nursing, science, and viticulture and enology.
it is not because of generic similarity; it is because that radiotherapy in its nature kills cancer cells with no species response differences; If ISOPET and later Radiogel prove effectiveness with very limited harm to collateral normal tissues, it for sure will be widely used in human cancer treatment. The indications and market then explode!!!
hope lucky enough
That is true. If this technology proves great effectiveness with very little side effects in animals, it surely goes to human soon.